Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy-Reference-Cited by-同舟云学术

Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy

Published:2020-11-26 Issue:12 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Carver Alicia B¹,Zuckerman Autumn D¹,DeClercq Joshua²,Choi Leena²^ORCID,Chastain Cody A³

Affiliation:

1. Specialty Pharmacy Services, Vanderbilt University Medical Center, Nashville, Tennessee, USA

2. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA

3. Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Abstract

Abstract Rates of persistent viremia (PV) while on direct-acting antiviral therapy were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (96.5%), without significant differences.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa569/34546416/ofaa569.pdf

Reference12 articles.

1. Hepatitis C virus RNA levels during interferon-free combination direct-acting antiviral treatment in registrational trials;Harrington;Clin Infect Dis,2015

2. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies;Malespin;Therap Adv Gastroenterol,2017

3. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C;Johnson;J Viral Hepat,2017

4. Real-world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive, genotype 1 hepatitis C-infected patients;Backus;Hepatology,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort;Digestive Diseases and Sciences;2022-05-13